facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2018
vol. 105
 
Share:
Send email
Share:
abstract:
Special paper

Cutaneous lupus erythematosus. Diagnostic and therapeutic recommendations of the Polish Dermatological Society

Anna Woźniacka
,
Anna Sysa-Jędrzejowska
,
Adam Reich
,
Jacek Szepietowski
,
Maria Błaszczyk
,
Anna Lis-Święty
,
Anna Wojas-Pelc
,
Dorota Krasowska
,
Joanna Maj
,
Lidia Rudnicka

Dermatol Rev/Przegl Dermatol 2018, 105, 244-263
DOI: https://doi.org/10.5114/dr.2018.75581
Online publish date: 2018/05/14
View full text Get citation
 
PlumX metrics:
Lupus erythematosus is an autoimmune disease with complex and not fully elucidated pathogenic mechanisms, the most important of which is the presence of antibodies directed against the autoantigens, particularly located within the cell nucleus, which precede the development of clinical symptoms. Lupus erythematosus either affects only the skin or skin lesions are one of the manifestations of a systemic process. The classification is based on morphological, histopathological and serological features, and the course of the disease. Depending on diverse clinical manifestations and differences in prognosis, therapeutic management needs to be adapted to the individual patient. Therapeutic guidelines include both lifestyle modifications (photoprotection, avoidance of infections, stress factors, phototoxic and photoallergic drugs, and oestrogens; supplementation with vitamin D), and topical (glucocorticosteroids, calcineurin inhibitors) and systemic medications. Antimalarials or systemic glucocorticosteroids are recommended in the treatment of patients with severe or disseminated lesions, with a tendency to scarring or a high risk of systemic organ involvement. Methotrexate, retinoids, sulphones and mycophenolate mofetil belong to second and third-line medications indicated for the treatment of cutaneous forms of lupus erythematosus.
keywords:

lupus erythematosus, consensus, Polish Dermatological Society
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Alergologia – kompendium


Indeks osobowy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.